2024-09-08 - Analysis Report
## JNJ Stock Analysis Report

**Company Overview:** Johnson & Johnson (JNJ) is a multinational pharmaceutical, medical device, and consumer packaged goods company. 

**Performance Analysis:**

1. **Performance vs. S&P 500:** JNJ's cumulative return of 18.69% lags behind the S&P 500's (VOO) return of 81.34%. This results in a negative divergence of -62.65, representing a relative performance of 20.28% compared to its historical range. This suggests JNJ has underperformed the broader market over the period.

2. **Recent Price Movement:**
    * Closing price: $164.38
    * 5-day moving average: $165.95
    * 20-day moving average: $162.45
    * 60-day moving average: $155.45
    
    The current price is slightly below the 5-day moving average, suggesting a potential short-term downtrend. However, it remains above both the 20-day and 60-day moving averages, indicating a longer-term upward trend. 

3. **Technical Indicators:**
    * RSI: 67.48 - This suggests the stock is currently in overbought territory, indicating potential for a short-term correction.
    * PPO: -0.02 - This indicates a weak short-term momentum.
    * Delta_Previous_Relative_Divergence: +0.12 - This suggests a potential short-term uptrend. 
    * Expected Return: 10.93% - This represents the potential maximum 5-year return based on current investment. 

4. **Recent Earnings & Outlook:**

| Date       | EPS  | Revenue        |
|------------|------|-----------------|
| 2024-07-25 | 1.95 | $22.45 Billion |
| 2024-05-01 | 1.35 | $21.38 Billion |
| 2024-02-16 | 1.68 | $21.39 Billion |
| 2023-10-27 | 10.32| $21.35 Billion |
| 2024-02-16 | 10.32| $21.35 Billion |

The most recent earnings report (2024-07-25) showed EPS of $1.95, which exceeded analysts' expectations of $1.84. Revenue also surpassed expectations, reaching $22.45 billion compared to the estimated $22.07 billion. 

**Overall Analysis:**

Despite underperforming the market in the long term, JNJ's recent performance shows positive signs. While the stock is currently in overbought territory and has weak short-term momentum, it has recently surpassed analysts' earnings expectations and continues to show a long-term upward trend.  Further analysis is needed to determine the potential impact of recent earnings on future performance. 
